Development and validation of HPLC‐ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium
Biomedical Chromatography · 2024
DOI: 10.1002/bmc.5888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Xiaoming Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Maternal-Fetal Pharmacology and Bio-Development Laboratories, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, T…. Hauptthemen laut MEDLINE: Placenta, Limit of Detection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
A simple and reliable HPLC‐ultraviolet (HPLC‐UV) method was developed and validated for the quantification of pritelivir in the samples of medium from the experiments utilizing the ex vivo technique of dual perfusion of the human placental lobule. Phenacetin was used as an internal standard (IS) in our HPLC‐UV method. Chromatographic separation of pritelivir and phenacetin was achieved on a Waters Symmetry C 18 HPLC column (100 × 2.1 mm, 3.5 μm) at ambient temperature (22–25°C). The mobile phase was composed of 50% methanol in deionized water (v/v), the flow rate for isocratic elution was established at 0.25 mL/min, and the detection wavelength for pritelivir and IS was set at 254 nm. Pritelivir and IS were extracted with the protein precipitation method using methanol as a solvent. The calibration curve for pritelivir exhibited linearity ( r 2 > 0.99) within the concentration range from 0.155 to 6.62 μg/mL. Within‐ and between‐day accuracy ranged from 97% to 110% with relative standard deviation (RSD) values not exceeding 10%. The extraction recovery of pritelivir and IS ranged from 89% to 91% with RSD not exceeding 7%. Pritelivir was stable under the storage and sample handling conditions. This validated HPLC‐UV method was utilized to quantify pritelivir in the placental perfusion medium samples, and the resulting concentrations were authenticated with incurred sample reanalysis to confirm the reliability of the method.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maternal-Fetal Pharmacology and Bio-Development Laboratories, Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, Texas, USA.
ORCID-Profile: Xiaoming Wang
Förderung
- NICHD NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Wang, X., Patrikeeva, S., Nanovskaya, T., & Bryant, V. (2024). Development and validation of HPLC‐ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium. Biomedical Chromatography. https://doi.org/10.1002/bmc.5888
Vancouver
Wang X, Patrikeeva S, Nanovskaya T, Bryant V. Development and validation of HPLC‐ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium. Biomedical Chromatography. 2024. doi:10.1002/bmc.5888
BibTeX
@article{Wang2024,
author = {Wang, Xiaoming and Patrikeeva, Svetlana and Nanovskaya, Tatiana and Bryant, Valentina},
title = {Development and validation of HPLC‐ultraviolet method for quantitative determination of pritelivir in human placental perfusion medium},
journal = {Biomedical Chromatography},
year = {2024},
doi = {10.1002/bmc.5888}
}
EUVIMED